EUCTR2016-003226-16-IT进行中（未招募）1 期
Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR aß+ T cells in pediatric patients affected by hematological disorders - CaspaCide TCR aß haplo HSCT
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed written informed consent by the patient or the patient’s guardian for children who are minors
- •2. enrolled on BP-004 protocol, received BPX-501 infusion and completed 6 months of active treatment
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 170
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Lack of parents’/guardian’s informed consent for children who are minors.
研究者
相似试验
进行中（未招募）
1 期
Phase II extension study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR aß+T cells in pediatric patients affected by hematological disordersAMLNon-Hodgkin lymphomaHematological disorders (ALLFanconi anemiaMyelodysplasticsyndromesCongenital immune deficienciesSevere aplastic anemiaOsteopetrosisSelected cases of hemoglobinopathies)MedDRA version: 19.1Level: HLGTClassification code 10018849Term: Haematological disorders NECSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-000584-41-ESBellicum Pharmaceuticals, Inc.175
进行中（未招募）
1 期
Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR aß+ T cells in pediatric patients affected by hematological disordersAMLFanconi anemiaNon-Hodgkin lymphomaHematological disorders (ALLMyelodysplasticsyndromesCongenital immune deficienciesSevere aplastic anemiaOsteopetrosisSelected cases of hemoglobinopathies)MedDRA version: 16.1Level: HLGTClassification code 10018849Term: Haematological disorders NECSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2014-000584-41-ITBellicum Pharmaceuticals, Inc.30
进行中（未招募）
1 期
Phase I/II study of CaspaCide T cells in children following aß- depleted mis-matched family donor stem cell transplantatioAMLNon-Hodgkin lymphomaFanconi anemiaEUCTR2014-000584-41-GBBellicum Pharmaceuticals, Inc.175
终止
1 期
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyLeukemia, Acute Myeloid (AML), ChildLymphoma, Non-HodgkinMyelodysplastic SyndromesPrimary ImmunodeficiencyAnemia, AplasticHemoglobinopathiesCytopeniaDiamond Blackfan AnemiaAnemia, Sickle CellAcute Lymphoblastic LeukemiaThalassemiaFanconi AnemiaNCT03733249Bellicum Pharmaceuticals187
已完成
2 期
Multicenter phase I/IIa study using T-cell receptor gene therapy in metastatic melanomamaligne melanomauveal melanoma1003005410040900skin cancerNL-OMON47165ederlands Kanker Instituut20